Drug Profile
Ziltivekimab - Novo Nordisk
Alternative Names: COR 001; NN 6018Latest Information Update: 25 Jan 2024
Price :
$50
*
At a glance
- Originator AstraZeneca
- Developer Novo Nordisk
- Class Anti-inflammatories; Cardiovascular therapies; Monoclonal antibodies; Urologics
- Mechanism of Action Interleukin 6 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Cardiovascular disorders; Heart failure; Inflammation; Kidney disorders
Most Recent Events
- 10 Jan 2024 Novo Nordisk plans a phase III ATHENA trial for Heart Failure and Inflammation in Argentina, Australia, Bulgaria, Canada, Czech Republic, France, Germany, Greece, India, Malaysia, Poland, Portugal, Spain, Turkey, United Kingdom, and USA (SC) in April 2024 (NCT06200207)
- 08 Jan 2024 Novo Nordisk completes a phase I pharmacokinetic trial (In volunteers) in Hungary, Netherlands (SC) (NCT05721989)
- 07 Nov 2023 Novo Nordisk plans a phase III ARTEMIS trial for Cardiovascular disorders and Heart failure in India (SC) in June 2024 (NCT06118281)